Jack Stover, CEO, Interpace Biosciences describes the changing landscape of drug development with the introduction of genetic data, creation of advanced diagnostic tests for pancreatic, thyroid, lung and esophageal cancers, and the resulting implications for treatment plans. He also explains their work with big pharma companies in the area of immuno-oncology to determine potential partnerships with other drug candidates.

@InterpaceBIO #IDXG #immunooncology #cancer

Interpace.com

Listen to the podcast here